Black Hawk Acquisition Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended August 31, 2026. The filing is dated October 6, 2026. Black Hawk is a blank-check company and has not commenced operations or generated operating revenue; its activity is pursuing a business combination.
Financial position and results
| Metric | August 31, 2026 / period | Comparison |
|---|---|---|
| Cash | $12,052 | $39,521 at November 30, 2025 |
| Trust investments | $25.99 million | $23.83 million at November 30, 2025 |
| Total assets | $26.03 million | $23.88 million at November 30, 2025 |
| Total liabilities | $4.75 million | $3.90 million at November 30, 2025 |
| Working capital deficit | $2.29 million | Reported at August 31, 2026 |
| Related-party convertible notes | $1.51 million carrying value, net of discount | $595,369 at November 30, 2025 |
| Redeemable public shares | 2,124,077 shares; $25.99 million redemption value ($12.24 per share) | Same share count; $23.83 million redemption value ($11.22 per share) at November 30, 2025 |
Revenue and earnings: No operating revenue. Net income was $1.07 million for the quarter, versus $154,401 in the 2025 quarter; for the nine months it was $1.30 million, versus $1.33 million in 2025. Basic and diluted earnings per share were $0.26 for the quarter and $0.31 for the nine months, compared with $0.03 and $0.17, respectively. Earnings included a $1.016 million gain from Vesicor’s debt forgiveness. Without this unusual gain, the reported profit picture would be materially different. No operating margins are meaningful because the company has no operating revenue.
Key income items: Trust interest income was $230,184 for the quarter and $666,151 for the nine months, compared with $494,519 and $2.03 million in the 2025 periods. General and administrative expense was $108,210 for the quarter and $211,613 for the nine months, down from $311,265 and $607,632. Related-party administrative fees were $30,000 and $90,000, respectively. Nine-month interest expense was $77,056.
Cash flow: Net cash used in operating activities was $459,590 for the nine months, compared with $549,842 used in 2025. Investing activities used $1.50 million, primarily for trust deposits; financing activities provided $1.93 million, including Sponsor notes and target-company advances. Ending cash was $12,052. The 2025 cash-flow comparison was significantly affected by approximately $51.0 million of trust withdrawals and payments for redeemed shares.
Changes and transaction developments
- Lower administrative and general expenses and the $1.016 million debt-forgiveness gain lifted quarterly net income. For the nine months, net income was slightly below 2025, as trust interest income fell substantially.
- In June 2026, Vesicor forgave $1,015,988 of advances made to or for Black Hawk through February 12, 2026. Black Hawk recorded the forgiveness as income. Later Vesicor advances were not covered by that agreement; the filing says no separate written agreement for those advances existed as of October 6, 2026.
- In July 2025, public shareholders redeemed 4,775,923 shares for approximately $51.0 million. The company reported approximately $22.7 million remaining in trust after those redemptions; subsequent extension deposits and trust earnings increased the August 2026 trust balance to $25.99 million.
- Black Hawk’s proposed business combination with Vesicor Therapeutics, an early-stage biotechnology company, values Vesicor at $70 million pre-money. Vesicor shareholders and management are to roll over all their equity and receive no cash proceeds under the stated transaction terms. Closing remains subject to approvals and other conditions.
Outlook, liquidity, risks and other material matters
- The S-4 registration statement became effective September 17, 2026; the definitive proxy statement/prospectus was filed September 22. A shareholder meeting was scheduled for October 13, 2026, and the company expected the transaction to close in the fourth quarter of 2026. These are plans, not assurances of completion.
- The company deposited a $150,000 extension payment on September 22, 2026, extending the business-combination deadline by one month to October 22, 2026. Its extension framework permits monthly extensions through December 22, 2026, subject to required deposits.
- Management concluded that substantial doubt exists about the company’s ability to continue as a going concern, citing minimal cash, a $2.29 million working-capital deficit, continuing public-company and transaction costs, and the risk that a business combination will not be completed before the deadline. The financial statements include no adjustments for the outcome of this uncertainty.
- Nasdaq notified the company in August 2026 that it had regained compliance with the minimum market-value listing requirement; the matter was closed.
- Related-party notes are unsecured, bear interest at 6% or 10%, and generally mature upon a business combination or liquidation. Upon a business combination, the Sponsor may elect to convert unpaid principal and interest at $1.00 per share. The filing estimates approximately 1.6 million shares issuable on conversion, including accrued interest; outstanding rights could add approximately 1.43 million shares. Both were excluded from diluted EPS as antidilutive or because conditions were unmet.
- Post-quarter agreements with Meteora include a forward purchase arrangement for up to 1.35 million shares, a non-redemption arrangement covering up to 2,124,077 shares, and a standby equity purchase agreement allowing—but not requiring—PubCo to sell up to $200 million of shares over generally 36 months. The non-redemption agreement requires best efforts, not a minimum share commitment. The standby facility is conditional and ordinary advances are generally priced at 97% of market price; it should not be treated as committed cash already available. The facility also carries a 0.50% commitment fee on the maximum amount, payable in cash or shares at PubCo’s election.
- Disclosure controls and procedures were assessed as ineffective at a reasonable-assurance level because formal internal controls, including segregation of duties and written accounting and reporting procedures, were not fully designed, implemented and documented. Management said it intends to continue developing these controls.
- The company disclosed no material pending litigation and no defaults upon senior securities. It reported no off-balance-sheet arrangements as of August 31, 2026.
Most important facts for investors to verify
- Whether shareholders approve the Vesicor transaction and all other closing conditions—including Nasdaq listing approval—are satisfied, and whether closing occurs before the extended deadline.
- The final trust balance, redemption level, extension funding, and actual cash available to the combined company after transaction payments and fees.
- The detailed effect of Meteora’s forward purchase and non-redemption arrangements on trust cash, share count, and post-closing ownership; neither arrangement guarantees the full stated share amount.
- Whether the $200 million standby equity facility is registered and usable, and the resulting dilution, pricing, fees, and any agreed pre-paid advances. The filing does not indicate that any such advance has been funded.
- The amount and treatment of Sponsor notes and accrued interest at closing, including any conversion at $1.00 per share, and the resulting dilution.
- How Black Hawk addresses its going-concern conditions and ineffective disclosure controls, and whether post-February 12, 2026 Vesicor advances have been documented and reconciled.